Subtype
Pharyngeal Neoplasm
CI-CAN-00001414Explore in graph →
Non-malignant421 active trials1 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001414Explore in graph →
Clinical trials
1,344 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07129772 | Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 53 | The University of Hong KongOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07138989 | EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 10 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07136519 | Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 30 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07137039 | Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen | not yet recruiting | Phase 2 | 34 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06688175 | IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma | enrolling by invitation | Phase 2 | 32 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma(PUPA) | not yet recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07085234 | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085988 | Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 109 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07067268 | Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy | recruiting | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05147844 | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06676722 | SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06811844 | Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC | recruiting | Phase 2 | 208 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06009861 | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | active not recruiting | Phase 2 | 110 | Peking University Hospital of StomatologyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06987123 | TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial | not yet recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT06912711 | TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06861712 | Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04875611 | Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment(NIVONASO-21) | recruiting | Phase 2 | 32 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05508347 | Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 170 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04517214 | Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06892431 | JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer | not yet recruiting | Phase 2 | 150 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06605131 | GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 72 | Sun Yat-sen UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04223024 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 246 | Sun Yat-sen UniversityOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06851247 | GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06781112 | A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 35 | Weiwei ZhangOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06349889 | Adebrelimab and Chemoradiotherapy in High-risk LANPC | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06472713 | Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC | recruiting | Phase 2 | 32 | Ming-Yuan ChenOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06657690 | Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC | recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06759155 | Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | University of Vermont Medical CenterOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06414577 | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy | active not recruiting | Phase 2 | 38 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752382 | Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC | not yet recruiting | Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06733948 | ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT03813394 | Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC(2018/00947) | active not recruiting | Phase 1 / Phase 2 | 48 | National University Hospital, SingaporeOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06680115 | Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 150 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06611137 | SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06611826 | GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC | not yet recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06554028 | Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer | not yet recruiting | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05193617 | Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06301165 | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 162 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490341 | GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT06455410 | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 216 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05513573 | Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC | active not recruiting | Phase 2 | 75 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06019130 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma(NPC-Nivo) | recruiting | Phase 2 | 57 | German Society for Pediatric Oncology and Hematology GPOH gGmbHOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06151743 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma | recruiting | Phase 2 | 32 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2025source: clinicaltrials